Related references
Note: Only part of the references are listed.A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1
Do-Youn Oh et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Adjuvant S-1 versus observation in curatively resected biliary tract cancer: A phase III trial (JCOG1202: ASCOT)
Masafumi Ikeda et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019 A Systematic Analysis for the Global Burden of Disease Study 2019
Jonathan M. Kocarnik et al.
JAMA ONCOLOGY (2022)
Targeting HER2 (ERBB2) mutation-positive advanced biliary tract cancers with neratinib: Results from the phase II SUMMIT 'basket' trial.
James J. Harding et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement.
Milind M. Javle et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Lenvatinib plus pembrolizumab for patients with previously treated biliary tract cancers in the multicohort phase II LEAP-005 study.
Luis Villanueva et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Targeting FGFR inhibition in cholangiocarcinoma
Lipika Goyal et al.
CANCER TREATMENT REVIEWS (2021)
Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliarytract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study
Changhoon Yoo et al.
LANCET ONCOLOGY (2021)
FGFR-TKI resistance in cancer: current status and perspectives
Sitong Yue et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study
Milind Javle et al.
Lancet Gastroenterology & Hepatology (2021)
Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial
Angela Lamarca et al.
LANCET ONCOLOGY (2021)
A randomised phase II study of oxaliplatin/5-FU (mFOLFOX) versus irinotecan/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine/cisplatin chemotherapy
In Sil Choi et al.
EUROPEAN JOURNAL OF CANCER (2021)
Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study
Milind Javle et al.
LANCET ONCOLOGY (2021)
Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation The Phase 3 Randomized Clinical ClarIDHy Trial
Andrew X. Zhu et al.
JAMA ONCOLOGY (2021)
Cell of origin in biliary tract cancers and clinical implications
Agrin Moeini et al.
JHEP REPORTS (2021)
NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls
James P. Solomon et al.
MODERN PATHOLOGY (2020)
Facts and New Hopes on Selective FGFR Inhibitors in Solid Tumors
Francesco Facchinetti et al.
CLINICAL CANCER RESEARCH (2020)
Pembrolizumab for advanced anal squamous cell carcinoma (ASCC): Results from the multicohort, phase II KEYNOTE-158 study
Aurelien Marabelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials
Robert C. Doebele et al.
LANCET ONCOLOGY (2020)
Efficacy and Safety of Pembrolizumab in Patients with Refractory Advanced Biliary Tract Cancer: Tumor Proportion Score as a Potential Biomarker for Response
Junho Kang et al.
CANCER RESEARCH AND TREATMENT (2020)
FOENIX-CCA2: A phase II, open-label, multicenter study of futibatinib in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 gene fusions or other rearrangements.
Lipika Goyal et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
Ghassan K. Abou-Alfa et al.
LANCET ONCOLOGY (2020)
A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer
Richard D. Kim et al.
JAMA ONCOLOGY (2020)
FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements
Tanios S. Bekaii-Saab et al.
FUTURE ONCOLOGY (2020)
Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF 301 trial
Shalini Makawita et al.
FUTURE ONCOLOGY (2020)
LEAP-005: Phase II study of lenvatinib (len) plus pembrolizumab (pembro) in patients (pts) with previously treated advanced solid tumours
Z. Lwin et al.
ANNALS OF ONCOLOGY (2020)
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
Jesus M. Banales et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2020)
Dabrafenib plus trametinib in patients with BRAF(V600E)-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial
Vivek Subbiah et al.
LANCET ONCOLOGY (2020)
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
Aurelien Marabelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study
Julien Edeline et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma
Paola Bertuccio et al.
JOURNAL OF HEPATOLOGY (2019)
Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study
John N. Primrose et al.
LANCET ONCOLOGY (2019)
Clinical presentation, diagnosis and staging of cholangiocarcinoma
Alejandro Forner et al.
LIVER INTERNATIONAL (2019)
Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors
Rastislav Bahleda et al.
CLINICAL CANCER RESEARCH (2019)
Increased multimodality treatment options has improved survival for Hepatocellular carcinoma but poor survival for biliary tract cancers remains unchanged
E. Alabraba et al.
EJSO (2019)
TAS-120 Overcomes Resistance to ATP-Compartitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholanjiocarcinoma
Lipika Goyal et al.
CANCER DISCOVERY (2019)
Cancer-associated mutation and beyond: The emerging biology of isocitrate dehydrogenases in human disease
Serena Tommasini-Ghelfi et al.
SCIENCE ADVANCES (2019)
Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma
Vincenzo Mazzaferro et al.
BRITISH JOURNAL OF CANCER (2019)
Regional differences in gallbladder cancer pathogenesis: Insights from a multi-institutional comparison of tumor mutations
Raja R. Narayan et al.
CANCER (2019)
Modified FOLFIRINOX versus CisGem first-line chemotherapy for locally advanced non resectable or metastatic biliary tract cancer (AMEBICA)-PRODIGE 38: Study protocol for a randomized controlled multicenter phase II/III study
Jean-Marc Phelip et al.
DIGESTIVE AND LIVER DISEASE (2019)
Biliary tract cancer: current challenges and future prospects
Michele Ghidini et al.
CANCER MANAGEMENT AND RESEARCH (2019)
Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review
Audra N. Boscoe et al.
JOURNAL OF GASTROINTESTINAL ONCOLOGY (2019)
A randomised phase II study of second-line XELIRI regimen versus irinotecan monotherapy in advanced biliary tract cancer patients progressed on gemcitabine and cisplatin
Yi Zheng et al.
BRITISH JOURNAL OF CANCER (2018)
Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer
T. Ebata et al.
BRITISH JOURNAL OF SURGERY (2018)
Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention
Maeve A. Lowery et al.
CLINICAL CANCER RESEARCH (2018)
Emerging Targeted Therapy for Tumors with NTRK Fusion Proteins
Ed S. Kheder et al.
CLINICAL CANCER RESEARCH (2018)
Circulating oncometabolite D-2-hydroxyglutarate enantiomer is a surrogate marker of isocitrate dehydrogenase-mutated intrahepatic cholangiocarcinomas
Julia Delahousse et al.
EUROPEAN JOURNAL OF CANCER (2018)
Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma
Milind Javle et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Role and targeting of anaplastic lymphoma kinase in cancer
Carminia Maria Della Corte et al.
MOLECULAR CANCER (2018)
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children
A. Drilon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial
Loic Verlingue et al.
EUROPEAN JOURNAL OF CANCER (2017)
Molecular mechanisms of isocitrate dehydrogenase 1 (IDH1) mutations identified in tumors: The role of size and hydrophobicity at residue 132 on catalytic efficiency
Diego Avellaneda Matteo et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2017)
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le et al.
SCIENCE (2017)
Gallbladder cancer epidemiology, pathogenesis and molecular genetics: Recent update
Aarti Sharma et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2017)
High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial
Christophe Massard et al.
CANCER DISCOVERY (2017)
Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma
Apinya Jusakul et al.
CANCER DISCOVERY (2017)
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
Eytan M. Stein et al.
BLOOD (2017)
Management and Outcomes of Patients with Recurrent Intrahepatic Cholangiocarcinoma Following Previous Curative-Intent Surgical Resection
Gaya Spolverato et al.
ANNALS OF SURGICAL ONCOLOGY (2016)
Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
J. W. Valle et al.
ANNALS OF ONCOLOGY (2016)
Biliary Cancer: Utility of Next-Generation Sequencing for Clinical Management
Milind Javle et al.
CANCER (2016)
Randomized Phase III study of gemcitabine plus S-1 versus gemcitabine plus cisplatin in advanced biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1113, FUGA-BT)
Junki Mizusawa et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2016)
Molecular Mechanisms and Translational Therapies for Human Epidermal Receptor 2 Positive Breast Cancer
Quanxia Lv et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
Pathologic classification of cholangiocarcinoma: New concepts
Yasuni Nakanuma et al.
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY (2015)
Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial
Alexander Stein et al.
BMC CANCER (2015)
HER2/neu-directed therapy for biliary tract cancer
Milind Javle et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
Genomic spectra of biliary tract cancer
Hiromi Nakamura et al.
NATURE GENETICS (2015)
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
David M. Hyman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
HER2 as a Therapeutic Target in Head and Neck Squamous Cell Carcinoma
Netanya I. Pollock et al.
CLINICAL CANCER RESEARCH (2015)
Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials
J. W. Valle et al.
ANNALS OF ONCOLOGY (2014)
Fibroblast Growth Factor Receptor 2 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Cholangiocarcinoma
Yasuhito Arai et al.
HEPATOLOGY (2014)
BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma
Benjamin Goeppert et al.
MODERN PATHOLOGY (2014)
Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway
Maolan Li et al.
NATURE GENETICS (2014)
Integrated Genomic Characterization Reveals Novel, Therapeutically Relevant Drug Targets in FGFR and EGFR Pathways in Sporadic Intrahepatic Cholangiocarcinoma
Mitesh J. Borad et al.
PLOS GENETICS (2014)
Regulation of neurotrophin receptor (Trk) signaling: suppressor of cytokine signaling 2 (SOCS2) is a new player
Rachel T. Uren et al.
Frontiers in Molecular Neuroscience (2014)
Molecular Pathways: ROS1 Fusion Proteins in Cancer
Kurtis D. Davies et al.
CLINICAL CANCER RESEARCH (2013)
Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas
P. Wang et al.
ONCOGENE (2013)
Molecular Pathways: Fibroblast Growth Factor Signaling: A New Therapeutic Opportunity in Cancer
A. Nigel Brooks et al.
CLINICAL CANCER RESEARCH (2012)
The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
Ethan Cerami et al.
CANCER DISCOVERY (2012)
Risk Factors for Cholangiocarcinoma
Gia L. Tyson et al.
HEPATOLOGY (2011)
Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan
T. Okusaka et al.
BRITISH JOURNAL OF CANCER (2010)
Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer
Jochen Weigt et al.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2010)
Epidemiology of biliary tract cancers: an update
G. Randi et al.
ANNALS OF ONCOLOGY (2009)
Trends in Presentation and Survival for Gallbladder Cancer During a Period of More Than 4 Decades A Single-Institution Experience
Ioannis T. Konstantinidis et al.
ARCHIVES OF SURGERY (2009)
S-1: a promising new oral fluoropyrimidine derivative
Muhammad Wasif Saif et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2009)
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Lenny Dang et al.
NATURE (2009)
The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis
M. M. Moasser
ONCOGENE (2007)
Gene amplification and protein overexpression of HER-2/neu in human extrahepatic cholangiocarcinoma as detected by chromogenic in situ hybridization and immunohistochemistry: its prognostic implication in node-positive patients
H. J. Kim et al.
ANNALS OF ONCOLOGY (2007)
Microsatellite instability and alternative genetic pathway in intrahepatic cholangiocarcinoma
H Momoi et al.
JOURNAL OF HEPATOLOGY (2001)
Share Paper
